FDA Approvals - Cancer Currents Blog

<!DOCTYPE html> <html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#"> <head> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta charset="utf-8" /> <script>window.CDEConfig = { "exitDisclaimerHref":{ "en":"\/policies\/linking", "es":"\/espanol\/politicas\/enlaces" }, "showFloatingDelighters":true, "environmentConfig":{ }, "glossaryConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/glossary\/v1\/" }, "drugDictionaryConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/drugdictionary\/v1\/" }, "ctsConfig":{ "apiServer":"https:\/\/clinicaltrialsapi.cancer.gov\/api\/v2", "printApiBase":"https:\/\/www.cancer.gov\/CTS.Print", "zipConversionEndpoint":"\/cts_api\/zip_code_lookup" }, "r4rConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/r4r\/v1" }, "general":{ "apiServer":"https:\/\/webapis.cancer.gov", "mediaServer":"https:\/\/nci-media.cancer.gov" }, "sitewideSearchConfig":{ "bestBetsApiServer":"https:\/\/webapis.cancer.gov\/bestbets\/v1\/", "searchApiServer":"https:\/\/webapis.cancer.gov\/sitewidesearch\/v1\/" }, "chartData": { "factBook": { "baseUrl": "\/about-nci\/budget\/fact-book", "dataType": "json" } } };</script> <script id="ncids-nav-info">window.ncidsNavInfo = { nav: { id: "860258", menu_type: "section-nav"}, item_id: 860258};</script> <meta name="description" content="The Cancer Currents blog provides news and research updates from the National Cancer Institute." /> <link rel="canonical" href="https://www.cancer.gov/news-events/cancer-currents-blog" /> <meta http-equiv="content-language" content="en" /> <meta name="robots" content="index" /> <meta property="og:type" content="Website" /> <meta property="og:url" content="https://www.cancer.gov/news-events/cancer-currents-blog" /> <meta property="og:title" content="FDA Approvals - Cancer Currents Blog" /> <meta property="og:description" content="The Cancer Currents blog provides news and research updates from the National Cancer Institute." /> <meta property="og:image" content="https://www.cancer.gov/sites/g/files/xnrzdm211/files/styles/cgov_social_media/public/cgov_image/media_image/2019-10/lab-tech-looking-at-stats-on-laptop.jpg" /> <meta name="cgdp.domain" content="cgov" /> <meta name="cgdp.template" content="default" /> <meta name="dcterms.subject" content="News and Events" /> <meta name="dcterms.type" content="cgvBlogSeries" /> <meta name="dcterms.coverage" content="nciglobal,ncienterprise" /> <meta name="dcterms.isPartOf" content="CancerCurrents" /> <meta name="dcterms.isReferencedBy" content="event1" /> <meta name="twitter:card" content="summary" /> <link rel="icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.ico" sizes="32x32"/> <link rel="icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.svg" type="image/svg+xml"/> <link rel="apple-touch-icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/apple-touch-icon.png"/> <link rel="manifest" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/site.webmanifest"/> <meta name="x-no-op" content="none" /> <meta name="Generator" content="Drupal 10 (https://www.drupal.org)" /> <meta name="MobileOptimized" content="width" /> <meta name="HandheldFriendly" content="true" /> <meta name="viewport" content="width=device-width, user-scalable=yes, initial-scale=1, minimum-scale=1" /> <script id="cgov-adobe-url" type="text/javascript" src="//assets.adobedtm.com/6a4249cd0a2c/949e98979342/launch-5f2a5357bf66.min.js" async="async"></script> <script type="application/ld+json">{ "@context": "https://schema.org", "@graph": [ { "@type": "WebSite", "name": "National Cancer Institute (.gov)", "url": "https://www.cancer.gov" } ] }</script> <link rel="alternate" hreflang="en" href="https://www.cancer.gov/news-events/cancer-currents-blog" /> <link rel="alternate" hreflang="es" href="https://www.cancer.gov/espanol/noticias/temas-y-relatos-blog" /> <title>FDA Approvals - Cancer Currents Blog - NCI</title> <link rel="preconnect" href="https://static.cancer.gov" /> <link rel="preconnect" href="https://fonts.googleapis.com"> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin> <link href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400;1,600;1,700&family=Poppins:ital,wght@0,300;0,400;0,500;0,600;1,300;1,400;1,500;1,600&family=Roboto+Mono:ital,wght@0,300;0,400;0,700;1,300;1,400;1,700&display=swap" rel="stylesheet"> <meta name="apple-mobile-web-app-title" content="Cancer.gov" /> <meta name="application-name" content="Cancer.gov" /> <link rel="stylesheet" media="all" href="/sites/g/files/xnrzdm211/files/css/css_0c3pwaxuQmeWVgPRWJtegrZ7sDiTQ8KSYZAxin88WNY.css?delta=0&language=en&theme=ncids_trans&include=eJwrriwuSc3VT0osTtUpy0wtL9YHk3q5-SmlOak6ecmZKcXxJUWJecX6STn56cUAzvIS5Q" /> <link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/ncids-common.css?smm34w" /> <link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/blogs.css?smm34w" /> </head> <body class="has-translated-content"> <a href="#main-content" class="usa-skipnav"> Skip to main content </a> <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas> <section id="usa-banner" class="usa-banner" aria-label="Official government website"> <header class="usa-banner__header"> <div class="usa-banner__inner"> <div class="usa-banner__header-text"> An official website of the United States government </div> <a href="/espanol/noticias/temas-y-relatos-blog?topic=aprobaciones-fda" id="lang-toggle" class="usa-button usa-button--nci-small" hreflang="es">Español</a> </div> </header> </section> <header id="nci-header" class="nci-header nci-header--megamenu" data-base-path="/"> <div class="nci-header__navbar"> <div class="nci-logo" id="extended-mega-logo"> <a href="/" aria-label="National Cancer Institute Home Page"> <picture><source media="(min-width: 1024px)" srcset="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI.svg" /> <img src="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI_Mobile.svg" alt="" /> </picture> </a> </div> <div class="nci-header-nav__secondary"> <button class="usa-button nci-header-mobilenav__open-btn">Menu</button> <form class="nci-header-search" method="get" action="/search/results" role="search"> <label class="usa-sr-only" for="nci-header-search__field"> Search </label> <input class="usa-input" id="nci-header-search__field" type="search" name="swKeyword" data-autosuggest-collection="cgov"/> <button class="usa-button nci-header-search__search-button" type="submit" aria-label="Search"> <span class="nci-header-search__label" aria-hidden="true">Search</span> <svg class="usa-icon" xmlns="http://www.w3.org/2000/svg" role="img" viewbox="0 0 24 24" aria-hidden="true"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z"/> </svg> </button> </form> </div> </div> <nav aria-label="Primary navigation" class="nci-header-nav"> <div class="nci-header-nav__inner"> <ul class="nci-header-nav__primary"> <li class="nci-header-nav__primary-item"> <a href="/about-cancer" class="nci-header-nav__primary-link" data-menu-id="829"> <span>About Cancer</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/types" class="nci-header-nav__primary-link" data-menu-id="11868"> <span>Cancer Types</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/research" class="nci-header-nav__primary-link" data-menu-id="12732"> <span>Research</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/grants-training" class="nci-header-nav__primary-link" data-menu-id="914792"> <span>Grants & Training</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/news-events" class="nci-header-nav__primary-link usa-current" data-menu-id="12664"> <span>News & Events</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/about-nci" class="nci-header-nav__primary-link" data-menu-id="10952"> <span>About NCI</span> </a> </li> </ul> </div> </nav> </header> <div class="grid-container"> <div class="grid-row flex-no-wrap"> <div class="grid-col-10"> <nav class="usa-breadcrumb usa-breadcrumb--wrap" aria-label="Breadcrumbs"> <ol class="usa-breadcrumb__list"> <li class="usa-breadcrumb__list-item"> <a href="/" class="usa-breadcrumb__link"> <span>Home</span> </a> </li> <li class="usa-breadcrumb__list-item"> <a href="/news-events" class="usa-breadcrumb__link"> <span>News & Events</span> </a> </li> <li class="usa-breadcrumb__list-item"> <a href="/news-events/cancer-currents-blog" class="usa-breadcrumb__link"> <span>Cancer Currents Blog</span> </a> </li> <li class="usa-breadcrumb__list-item usa-current" aria-current="page"> <span>Cancer Currents: An NCI Cancer Research Blog</span> </li> </ol> </nav> </div> <section class="cgdp-page-options cgdp-page-options--top" aria-label="Page options top"> <button class="usa-button usa-button--unstyled" onclick="window.print()"> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/> </svg> <span class="usa-sr-only"> Print </span> </button> <a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/news-events/cancer-currents-blog %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/> </svg> <span class="usa-sr-only"> Email </span> </a> </section> </div> </div> <div id="page" class="grid-container"> <div class="grid-row grid-gap"> <div data-drupal-messages-fallback class="hidden"></div> <div class="cgdpl desktop:grid-col-9"> <main id="main-content" class="contentzone"> <div>  <article> <div class="resize-content"> <h1> <span> FDA Approvals - Cancer Currents Blog </span> </h1> <div id="nvcgSubTitle"> <div class="subscribeRSS"> <a class="blogRSS" href="https://public.govdelivery.com/accounts/USNIHNCI/subscriber/new?topic_id=USNIHNCI_38"><span>Subscribe</span></a> </div> </div> <div id="cgvBody" class="cgvtopicpage"> <div class="slot-item first-SI"> <div class="blog-intro-text"> <p>News on recent approvals of cancer therapies by the Food and Drug Administration. Includes expert comments on how the approval will influence patient care and future research.</p> </div> </div> <div class="slot-item last-SI"> <div class="dynamic list has-images"> <ul> <div class="views-element-container"><div class="js-view-dom-id-68ee1fa57cb7702bcd24341b88d4867952bf4c65ed2fb3e63b56a64ef854b2ed"> <div class="item-list"> <ul> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/shield-blood-test-colorectal-cancer-screening"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-10/blood%20draw.jpg?h=169661cb&itok=IIrBJgYf" width="228" height="171" alt="An image of a patient's arm with a blue tourniquet and nurse, arm and part of her body visible only, drawing blood." /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/shield-blood-test-colorectal-cancer-screening" onclick=""> <span>Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In?</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-10-11T12:00:00Z">October 11, 2024</time>, by Alyssa Voss </div> <p>FDA recently approved the Shield test, the first blood test for the primary screening of people at average risk of colorectal cancer. Where does it fit in with other screening options for the disease, including colonoscopy and stool tests?</p> <p><a href="/news-events/cancer-currents-blog/2024/shield-blood-test-colorectal-cancer-screening">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-08/patients-t-cell.jpg?h=97ac484f&itok=CvPn9tXi" width="228" height="171" alt="Illustration of the components of a T-cell therapy: An enhanced T-cell receptor from a patient's T cell binds to an HLA antigen on the surface of a cancer cell. " /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4" onclick=""> <span>FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-08-27T12:00:00Z">August 27, 2024</time>, by Edward Winstead </div> <p>FDA approved afami-cel (Tecelra) to treat metastatic synovial sarcoma, a type of soft tissue sarcoma. The approval is for patients who have already received chemo and whose tumors are positive for MAGE-A4. Afami-cel is the first T-cell receptor therapy approved for cancer.</p> <p><a href="/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-08/Immune%20cell%20killing%20cancer%20cell2_0.jpg?h=d017d680&itok=LPtBVKfX" width="228" height="171" alt="A stylized image of an immune cell attacking a cancer cell." /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy" onclick=""> <span>More Immunotherapy Options Approved for Treating Endometrial Cancer</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-08-06T12:00:00Z">August 6, 2024</time>, by Sharon Reynolds </div> <p>People with advanced endometrial cancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with chemotherapy, for tumors with a genetic change called mismatch repair deficiency. The agency also expanded the approved uses of dostarlimab for the disease. </p> <p><a href="/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/pediatric-low-grade-glioma-tovorafenib-braf"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-05/occ-cc-tumor-open-access-image-edit-052024.png?h=1e6eb8d0&itok=UHQxEA6i" width="228" height="171" alt="An MRI scan showing a side view of a child with a low-grade glioma in the lower back of the brain. " /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/pediatric-low-grade-glioma-tovorafenib-braf" onclick=""> <span>Tovorafenib Approved for Some Children with Low-Grade Glioma</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-05-28T12:00:00Z">May 28, 2024</time>, by Sharon Reynolds </div> <p>FDA has granted an accelerated approval to tovorafenib (Ojemda) for kids and teens who have low-grade glioma with changes in the BRAF gene. In a small clinical trial, the drug shrank or completely eliminated tumors in nearly 70% of patients.</p> <p><a href="/news-events/cancer-currents-blog/2024/pediatric-low-grade-glioma-tovorafenib-braf">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/fda-alectinib-lung-cancer-alk-positive"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-05/stage%202b%20NSCLC-3.JPG?h=c167029a&itok=xpyEN5nb" width="228" height="171" alt="Illustration of a male figure showing the anatomy of the lungs with stage 2B lung cancer" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/fda-alectinib-lung-cancer-alk-positive" onclick=""> <span>Alectinib Approved as an Adjuvant Treatment for Lung Cancer</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-05-08T12:00:00Z">May 8, 2024</time>, by Sharon Reynolds </div> <p>FDA has approved alectinib (Alecensa) as adjuvant therapy for people with lung cancer who have ALK-positive tumors. In a clinical trial, alectinib helped people live longer after surgery without their cancer returning than chemotherapy.</p> <p><a href="/news-events/cancer-currents-blog/2024/fda-alectinib-lung-cancer-alk-positive">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/fda-enhertu-her2-positive-solid-tumors"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-04/iStock%20female%20doctor%20with%20older%20black%20male%20patient.jpg?h=6f9d72ee&itok=1lYdEzmu" width="228" height="171" alt="A young female doctor shows information on a tablet computer to an older black male patient." /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/fda-enhertu-her2-positive-solid-tumors" onclick=""> <span>FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-05-03T12:00:00Z">May 3, 2024</time>, by Carmen Phillips </div> <p>Trastuzumab deruxtecan (Enhertu) can now be used to treat any advanced solid cancer that produces high levels of the protein HER2 (HER2-positive tumors). FDA’s accelerated approval was based on findings from three clinical trials.</p> <p><a href="/news-events/cancer-currents-blog/2024/fda-enhertu-her2-positive-solid-tumors">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/fda-elahere-platinum-resistant-ovarian-cancer"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-04/ADC-drug-CancerCurrents.PNG?h=ba3b6c8c&itok=GyxV3DND" width="228" height="171" alt="" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/fda-elahere-platinum-resistant-ovarian-cancer" onclick=""> <span>Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-04-24T12:00:00Z">April 24, 2024</time>, by Linda Wang </div> <p>FDA approved mirvetuximab soravtansine-gynx (Elahere) to treat people with advanced, platinum-resistant ovarian cancer whose tumors overproduce a protein called FR-α. The full approval was based on the results of a large, randomized trial called MIRASOL, which showed Elahere improved survival for these people.</p> <p><a href="/news-events/cancer-currents-blog/2024/fda-elahere-platinum-resistant-ovarian-cancer">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-03/CC-Lifileucel%20FDA%20approval_Promo%20Image%204x3.jpg?h=6a76169e&itok=H8ak3-cT" width="228" height="171" alt="Tumor-infiltrating lymphocyte therapy or TIL" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma" onclick=""> <span>First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-03-05T12:00:00Z">March 5, 2024</time>, by Carmen Phillips </div> <p>In an event more than three decades in the making, FDA has approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes, or TILs.</p> <p><a href="/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/repotrectinib-lung-cancer-ros1"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-02/lung%20tumor%20illustration.jpg?h=248c7886&itok=fjoLBNPU" width="228" height="171" alt="A stylized chest x-ray illustration showing a bright orange tumor in the right lung." /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/repotrectinib-lung-cancer-ros1" onclick=""> <span>Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-02-16T12:00:00Z">February 16, 2024</time>, by Edward Winstead </div> <p>The results of the clinical trial that led to FDA’s 2023 approval of repotrectinib (Augtyro) for lung cancers with ROS1 fusions have been published. The drug shrank tumors in 80% of people receiving the drug as an initial treatment.</p> <p><a href="/news-events/cancer-currents-blog/2024/repotrectinib-lung-cancer-ros1">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/fda-xtandi-prostate-cancer-psa-recurrence"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2024-01/Doctor%20talking%20with%20male%20patient%20-%20enza%20expanded%20approval.jpg?h=ba09f060&itok=CZRsoR-z" width="228" height="171" alt="An older male doctor talking with a middle-aged male patient." /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/fda-xtandi-prostate-cancer-psa-recurrence" onclick=""> <span>Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-01-05T12:00:00Z">January 5, 2024</time>, by Carmen Phillips </div> <p>Under a new FDA approval, enzalutamide (Xtandi) can now be used alone, or in combination with leuprolide, to treat people with nonmetastatic prostate cancer that is at high risk of returning after surgery or radiation.</p> <p><a href="/news-events/cancer-currents-blog/2024/fda-xtandi-prostate-cancer-psa-recurrence">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2024/fda-toripalimab-nasopharyngeal-cancer"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2023-12/Cancer%20Currents-nasopharyngeal%20carcinoma-.jpg?h=1e6eb8d0&itok=2vVfcli2" width="228" height="171" alt="Imaging scans of a nasopharyngeal carcinoma with radiation doses presented in different colors" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/fda-toripalimab-nasopharyngeal-cancer" onclick=""> <span>Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer</span> </a> <div class="description"> <div class="date-author"> <time datetime="2024-01-03T12:00:00Z">January 3, 2024</time>, by Elia Ben-Ari </div> <p>FDA approved toripalimab (Loqtorzi) based on the results of a large clinical trial showing that, when added to chemotherapy, the drug extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.</p> <p><a href="/news-events/cancer-currents-blog/2024/fda-toripalimab-nasopharyngeal-cancer">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2023/fda-pembrolizumab-stomach-esophageal-her2-pdl1"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2023-11/esophagus%20GEJ%20stomach%20iStock.jpg?h=4366ed2c&itok=zGN_1pzC" width="228" height="171" alt="A conceptual imaging scan of a chest with the esophagus and stomach highlighted in red" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2023/fda-pembrolizumab-stomach-esophageal-her2-pdl1" onclick=""> <span>FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction Cancer</span> </a> <div class="description"> <div class="date-author"> <time datetime="2023-11-17T12:00:00Z">November 17, 2023</time>, by Carmen Phillips </div> <p>FDA has changed its 2021 approval of pembrolizumab (Keytruda) along with trastuzumab (Herceptin) and chemotherapy for treating HER2-positive stomach or GEJ cancer. The agency also announced a new approval of pembrolizumab for HER2-negative forms of these same cancers.</p> <p><a href="/news-events/cancer-currents-blog/2023/fda-pembrolizumab-stomach-esophageal-her2-pdl1">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2023-08/OCC-flt3-mutations.jpg?h=7d275b0f&itok=BrbZPJ9-" width="228" height="171" alt="An illustration depicting the ITD and TKD mutations in FLT3 in a cell membrane" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3" onclick=""> <span>Quizartinib Approval Adds New Treatment Option for AML, Including in Older Patients</span> </a> <div class="description"> <div class="date-author"> <time datetime="2023-08-15T12:00:00Z">August 15, 2023</time>, by Carmen Phillips </div> <p>Treatment options for people with acute myeloid leukemia (AML) have expanded yet again. On July 20, FDA approved quizartinib (Vanflyta) combined with chemotherapy as a first-line treatment for AML with a specific change in the FLT3 gene.</p> <p><a href="/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2023/fda-talazoparib-enzalutamide-prostate-cancer"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2023-08/DNA-break-PARP-inhibitor.png?h=a712854a&itok=Fn6cFE4k" width="228" height="171" alt="Illustration of DNA with a single strand break and PARP protein being blocked by a PARP inhibitor" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2023/fda-talazoparib-enzalutamide-prostate-cancer" onclick=""> <span>FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers</span> </a> <div class="description"> <div class="date-author"> <time datetime="2023-08-04T12:00:00Z">August 4, 2023</time>, by Shana Spindler </div> <p>FDA approved enzalutamide (Xtandi) combined with talazoparib (Talzenna) for metastatic castration-resistant prostate cancer with alterations in any of 12 DNA repair genes. The drug combination, which blocks both DNA repair activities and hormones that fuel cancer growth, was more effective than the standard treatment in a large clinical trial.</p> <p><a href="/news-events/cancer-currents-blog/2023/fda-talazoparib-enzalutamide-prostate-cancer">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2023-02/OCC-Cancer-Currents-HER2-Overexpression.jpg?h=1e6eb8d0&itok=ZNcBhrhd" width="228" height="171" alt="An illustration showing two cancer cells side by side with different amounts of HER2 on its surface." /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer" onclick=""> <span>Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer</span> </a> <div class="description"> <div class="date-author"> <time datetime="2023-02-10T12:00:00Z">February 10, 2023</time>, by Sharon Reynolds </div> <p>FDA approved tucatinib (Tukysa) with trastuzumab (Herceptin) to treat HER2-positive advanced colorectal cancer. The approval was based on the MOUNTAINEER trial, in which nearly 40% of participants’ tumors shrank after receiving the drug combination.</p> <p><a href="/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2023/fda-zanubrutinib-cll-sll"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2023-01/zanubrutinib-heart-related-side-effects.jpg?h=3bc30d04&itok=HUsU1jvM" width="228" height="171" alt="A health provider holding a stethoscope to a woman's chest." /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2023/fda-zanubrutinib-cll-sll" onclick=""> <span>Zanubrutinib’s Approval Improves Targeted Treatment for CLL</span> </a> <div class="description"> <div class="date-author"> <time datetime="2023-01-27T12:00:00Z">January 27, 2023</time>, by Shana Spindler </div> <p>FDA has approved zanubrutinib (Brukinsa) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) based on results from two clinical trials. In both trials, the drug, which blocks a protein called BTK, was more effective and caused fewer side effects than other treatments.</p> <p><a href="/news-events/cancer-currents-blog/2023/fda-zanubrutinib-cll-sll">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2023/blincyto-leukemia-minimal-residual-disease"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2023-01/Blinatumomab%20MOA2.PNG?h=d29dd11b&itok=E3IBkX86" width="228" height="171" alt="Illustration depicting mechanism of action of blinatumomab (Blincyto)" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2023/blincyto-leukemia-minimal-residual-disease" onclick=""> <span>Trial Suggests Expanded Role for Blinatumomab in Treating ALL</span> </a> <div class="description"> <div class="date-author"> <time datetime="2023-01-25T12:00:00Z">January 25, 2023</time>, by Linda Wang </div> <p>The immunotherapy drug blinatumomab (Blincyto) extends life for people with acute lymphoblastic leukemia who are in remission, even those with no signs of disease after initial treatment, a trial has found.</p> <p><a href="/news-events/cancer-currents-blog/2023/blincyto-leukemia-minimal-residual-disease">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2022/fda-brentuximab-children-hodgkin-lymphoma"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2022-12/DCTD-brentuximab.png?h=8901dc45&itok=qEnopPOK" width="228" height="171" alt="An illustration of brentuximab's mechanism of action." /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2022/fda-brentuximab-children-hodgkin-lymphoma" onclick=""> <span>Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents</span> </a> <div class="description"> <div class="date-author"> <time datetime="2022-12-15T12:00:00Z">December 15, 2022</time>, by Edward Winstead </div> <p>Based on an NCI-sponsored clinical trial conducted by the Children’s Oncology Group, FDA has approved the drug brentuximab vedotin (Adcetris) in combination with chemotherapy for some children and adolescents with Hodgkin lymphoma.</p> <p><a href="/news-events/cancer-currents-blog/2022/fda-brentuximab-children-hodgkin-lymphoma">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2022/fda-sodium-thiosulfate-cisplatin-hearing-loss-children"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2022-10/child-hearing-test.jpg?h=df6faf29&itok=KPfQXzTM" width="228" height="171" alt="" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2022/fda-sodium-thiosulfate-cisplatin-hearing-loss-children" onclick=""> <span>Sodium Thiosulfate Approved to Reduce Chemo-Related Hearing Loss in Children with Cancer</span> </a> <div class="description"> <div class="date-author"> <time datetime="2022-10-06T12:00:00Z">October 6, 2022</time>, by Edward Winstead </div> <p>The chemotherapy cisplatin often causes permanent hearing loss. Sodium thiosulfate (Pedmark) is the first treatment approved by FDA that can reduce the risk of hearing loss and the severity of damage to the inner ear in children treated with cisplatin.</p> <p><a href="/news-events/cancer-currents-blog/2022/fda-sodium-thiosulfate-cisplatin-hearing-loss-children">Continue Reading ></a></p> </div> </div> </li> </li> <li> <li class="general-list-item general list-item"> <div class="list-item-image image container"> <a class="item-image image" href="/news-events/cancer-currents-blog/2022/fda-lung-cancer-enhertu-her2"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_thumbnail/public/cgov_image/media_image/2022-09/ADC%20structure.PNG?h=2c2a16ec&itok=EkEzg3nE" width="228" height="171" alt="Un dibujo de la estructura de un conjugado de anticuerpo y fármaco" /> </a> </div> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2022/fda-lung-cancer-enhertu-her2" onclick=""> <span>Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer</span> </a> <div class="description"> <div class="date-author"> <time datetime="2022-09-13T12:00:00Z">September 13, 2022</time>, by Nadia Jaber </div> <p>On August 11, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with non-small cell lung cancer (NSCLC) that has a specific mutation in the HER2 gene. Around 3% of people with NSCLC have this kind of HER2 mutation.</p> <p><a href="/news-events/cancer-currents-blog/2022/fda-lung-cancer-enhertu-her2">Continue Reading ></a></p> </div> </div> </li> </li> </ul> </div> <div class="blog-pager clearfix"> <a class="older" href="/news-events/cancer-currents-blog?topic=fda-approvals&page=1">< Older Posts</a> </div> </div> </div> </ul> </div> </div> </div> </div> <footer class="article-footer"> </footer> </article>  </div> </main> </div>   <div class="cgdpl desktop:grid-col-3"> <div id="nvcgSlListBlogRTRail" class="right-rail"> <div class="slot-item"> <div class="managed list with-date"> <h2 id="Featured+Posts">Featured Posts</h2> <ul> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/medical-cannabis-oncologists-patients-communication">Oncologists Struggle to Answer Questions About Medical Cannabis</a> <div class="byline"> <p> October 16, 2024, by Carmen Phillips </p> </div> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/mammogram-false-positives-affect-future-screening">Mammogram False Positives Can Affect Future Screening Behavior</a> <div class="byline"> <p> October 4, 2024, by Edward Winstead </p> </div> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/ancient-retrovirus-dna-ltr10-cancer">DNA From an Ancient Virus Helps Many Cancers Grow</a> <div class="byline"> <p> September 6, 2024, by Nadia Jaber </p> </div> </div> </li> </ul> </div> </div> <div class="slot-item"> <div class="managed list without-date"> <h2 id="Categories">Categories</h2> <ul> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=biology">Biology of Cancer</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=cancer-risk">Cancer Risk</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=childhood-cancer">Childhood Cancer</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=clinical-trial-results">Clinical Trial Results</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=disparities">Disparities</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=fda-approvals">FDA Approvals</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=global-health">Global Health</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=leadership-expert-views">Leadership & Expert Views</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=prevention">Prevention</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=prognosis">Prognosis</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=screening-early-detection">Screening & Early Detection</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=survivorship-supportive-care">Survivorship & Supportive Care</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=technology">Technology</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=treatment">Treatment</a> </div> </li> </ul> </div> </div> <div class="slot-item"> <div class="desktop"> <div id="blog-archive-accordion"> <h2 id="archive" class="blog-archive-header"> Archive </h2> <div id="blog-archive-accordion-year"> <h3> 2024 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=11"> November </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=09"> September </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=08"> August </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=07"> July </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=06"> June </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=04"> April </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=02"> February </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=01"> January </a> (6) </li> </ul> <h3> 2023 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=11"> November </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=09"> September </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=01"> January </a> (6) </li> </ul> <h3> 2022 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=10"> October </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=09"> September </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=08"> August </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=03"> March </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=01"> January </a> (6) </li> </ul> <h3> 2021 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=11"> November </a> (4) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=09"> September </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=06"> June </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=04"> April </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=02"> February </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=01"> January </a> (6) </li> </ul> <h3> 2020 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=10"> October </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=09"> September </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=08"> August </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=07"> July </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=05"> May </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=04"> April </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=01"> January </a> (7) </li> </ul> <h3> 2019 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=12"> December </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=10"> October </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=09"> September </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=07"> July </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=06"> June </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=03"> March </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=02"> February </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=01"> January </a> (6) </li> </ul> <h3> 2018 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=12"> December </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=11"> November </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=10"> October </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=09"> September </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=08"> August </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=07"> July </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=06"> June </a> (12) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=04"> April </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=03"> March </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=02"> February </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=01"> January </a> (10) </li> </ul> </div> </div> </div> </div> </div> </div>  </div> <section class="cgdp-page-options cgdp-page-options--bottom" aria-label="Page options bottom"> <button class="usa-button usa-button--unstyled" onclick="window.print()"> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/> </svg> <span class="usa-sr-only"> Print </span> </button> <a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/news-events/cancer-currents-blog %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/> </svg> <span class="usa-sr-only"> Email </span> </a> </section> </div> <div id="block-ncidsfooterenglish"> <footer class="usa-footer usa-footer--nci-big" id="nci-footer" aria-label="Footer" > <div class="grid-container usa-footer__return-to-top"> <a href="#top" aria-label="Back To Top"><span>Back To Top</span></a> </div> <div class="usa-footer__primary-section"> <div class="grid-container"> <div class="grid-row grid-gap"> <div class="tablet:grid-col-8"> <nav class="usa-footer__nav" aria-label="Footer navigation"> <div class="grid-row grid-gap-4"> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">About</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/about-website">About This Website</a> </li> <li class="usa-footer__secondary-link"> <a href="/espanol">en Español</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/copyright-reuse">Reuse & Copyright</a> </li> <li class="usa-footer__secondary-link"> <a href="/social-media">Social Media</a> </li> </ul> </section> </div> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">Resources</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/contact">Contact Us</a> </li> <li class="usa-footer__secondary-link"> <a href="/publications">Publications</a> </li> <li class="usa-footer__secondary-link"> <a href="/publications/dictionaries/cancer-terms" >Dictionary of Cancer Terms</a > </li> <li class="usa-footer__secondary-link"> <a href="/research/participate/clinical-trials-search" >Find a Clinical Trial</a > </li> </ul> </section> </div> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">Policies</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/policies/accessibility">Accessibility</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/foia">FOIA</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/privacy-security" >Privacy & Security</a > </li> <li class="usa-footer__secondary-link"> <a href="/policies/disclaimer">Disclaimers</a> </li> <li class="usa-footer__secondary-link"> <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure</a > </li> </ul> </section> </div> </div> </nav> </div> <div class="tablet:grid-col-4"> <div class="usa-sign-up"> <div class="usa-sign-up__heading">Sign up for email updates</div> <form action="https://public.govdelivery.com/accounts/USNIHNCI/subscribers/qualify" aria-label="Footer subscribe" class="usa-form" accept-charset="UTF-8" method="post" novalidate target="_blank" id="signup" > <input type="hidden" name="category_id" id="category_id" value="" /> <div class="usa-form-group"> <label class="usa-label" for="email"> Enter your email address </label> <input class="usa-input width-full" id="email" name="email" type="email" value="" /> </div> <button class="usa-button usa-button--accent-warm" type="submit"> Sign up </button> </form> </div> </div> </div> </div> </div> <div class="usa-footer__secondary-section"> <div class="grid-container"> <div class="grid-row grid-gap"> <div class="usa-footer__logo grid-row desktop:grid-col-5"> <div class="mobile-lg:grid-col-auto desktop:margin-bottom-3"> <p class="usa-footer__logo-heading"> <span class="logo__agency-name">National Cancer Institute </span> <span class="logo__parent-organization" >at the National Institutes of Health</span > </p> </div> </div> <div class="usa-footer__contact-links mobile-lg:grid-col-7"> <div class="usa-footer__contact-heading">Contact Us</div> <div class="usa-footer__address"> <div class="usa-footer__contact-info grid-row grid-gap"> <div class="tablet:grid-col-auto"> <a href="https://livehelp.cancer.gov/">Live Chat</a> </div> <div class="tablet:grid-col-auto"> <a href="tel:1-800-4-CANCER">1-800-4-CANCER</a> </div> <div class="tablet:grid-col-auto"> <a href="mailto:NCIinfo@nih.gov">NCIinfo@nih.gov</a> </div> <div class="tablet:grid-col-auto"> <a class="no-exit-notification" href="https://nci.az1.qualtrics.com/jfe/form/SV_aeLLobt6ZeGVn5I" target="_blank" >Site Feedback</a > </div> </div> </div> </div> </div> <div class="grid-row grid-gap"> <div class="usa-footer__social-links desktop:grid-col-5"> <div class="usa-footer__social-heading">Follow us</div> <div class="grid-row grid-gap-1 nci-big__social"> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.facebook.com/cancer.gov" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-labelledby="facebook-title" > <title id="facebook-title">Facebook</title> <rect fill="none" height="24" width="24" /> <path d="M22,12c0-5.52-4.48-10-10-10S2,6.48,2,12c0,4.84,3.44,8.87,8,9.8V15H8v-3h2V9.5C10,7.57,11.57,6,13.5,6H16v3h-2 c-0.55,0-1,0.45-1,1v2h3v3h-3v6.95C18.05,21.45,22,17.19,22,12z" /> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://twitter.com/thenci" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="x-title" > <title id="x-title">Follow on X</title> <path d="M12 22c5.5 0 10-4.5 10-10S17.5 2 12 2 2 6.5 2 12s4.5 10 10 10zm5.2-15.6L13.3 11l4.3 6.2h-3.1L11.6 13 8 17.2h-.9l4.1-4.8-4.1-6h3.1l2.7 3.9 3.4-3.9h.9zm-5.6 5.4.4.6 2.8 4h1.4l-3.5-5-.4-.6-2.6-3.7H8.3l3.3 4.7z" /> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.instagram.com/nationalcancerinstitute/" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="instagram-title" > <title id="instagram-title">Instagram</title> <g id="Instagram"> <path d="M12,10a2,2,0,1,0,2,2A2,2,0,0,0,12,10Z" /> <path d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm6,12.69A3.32,3.32,0,0,1,14.69,18H9.31A3.32,3.32,0,0,1,6,14.69V9.31A3.32,3.32,0,0,1,9.31,6h5.38A3.32,3.32,0,0,1,18,9.31Z" /> <path d="M16.94,9.31a2.25,2.25,0,0,0-2.25-2.25H9.31A2.25,2.25,0,0,0,7.06,9.31v5.38a2.25,2.25,0,0,0,2.25,2.25h5.38a2.25,2.25,0,0,0,2.25-2.25h0ZM12,15.09A3.09,3.09,0,1,1,15.09,12,3.09,3.09,0,0,1,12,15.09Zm3.77-5.75a.79.79,0,0,1-.55.23.83.83,0,0,1-.55-.23.78.78,0,0,1,0-1.11A.82.82,0,0,1,15.22,8a.78.78,0,0,1,.55,1.33Z" /> </g> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.youtube.com/NCIgov" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="youtube-title" > <title id="youtube-title">Youtube</title> <g id="YouTube"> <path d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5.75,12.91A1.49,1.49,0,0,1,16.69,16a34.65,34.65,0,0,1-4.69.26A34.65,34.65,0,0,1,7.31,16a1.49,1.49,0,0,1-1.06-1.06A15.88,15.88,0,0,1,6,12a15.88,15.88,0,0,1,.25-2.91A1.49,1.49,0,0,1,7.31,8,34.65,34.65,0,0,1,12,7.77,34.65,34.65,0,0,1,16.69,8a1.49,1.49,0,0,1,1.06,1.06A15.88,15.88,0,0,1,18,12,15.88,15.88,0,0,1,17.75,14.91Z" /> <polygon points="10.77 13.78 13.91 12 10.77 10.22 10.77 13.78" /> </g> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.linkedin.com/company/nationalcancerinstitute/" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="linkedin-title" > <title id="linkedin-title">Linkedin</title> <g id="final"> <path d="M12,2C6.48,2,2,6.48,2,12s4.48,10,10,10s10-4.48,10-10S17.52,2,12,2z M8.912001,17.584H6.584v-7.472h2.328001V17.584z M7.744,9.104C6.992,9.104,6.4,8.488,6.4,7.76c0-0.752,0.592-1.344,1.344-1.344c0.728,0,1.343999,0.592,1.343999,1.344 C9.087999,8.488,8.472,9.104,7.744,9.104z M17.6,17.584h-2.328v-3.64c0-0.856-0.024001-1.967999-1.216001-1.967999 s-1.392,0.927999-1.392,1.912v3.696H10.36v-7.472h2.224v1.008h0.024c0.464-0.752,1.296-1.216001,2.199999-1.192 c2.352001,0,2.792,1.552001,2.792,3.544001C17.6,13.472,17.6,17.584,17.6,17.584z" /> </g> </svg> </a> </div> </div> </div> <div class="usa-footer__contact-links desktop:grid-col-7"> <div class="usa-footer__address height-full"> <div class="usa-footer__contact-info grid-row grid-gap height-full"> <address> <a href="https://www.hhs.gov/" >U.S. Department of Health and Human Services </a> <a href="https://www.nih.gov/" >National Institutes of Health </a> <a href="https://www.cancer.gov/">National Cancer Institute </a> <a href="https://usa.gov/">USA.gov</a> </address> </div> </div> </div> </div> </div> </div> </footer> </div> </div> <script src="/sites/g/files/xnrzdm211/files/js/js_qW3TLjdEty3QtOepUCSY4uh6BQEGkRIL3qUMnp3WXG4.js?scope=footer&delta=0&language=en&theme=ncids_trans&include=eJwrriwuSc3VT0osTtUpy0wtL9YHk3q5-SmlOak6ecmZKcXxJUWJecX6STn56cUAzvIS5Q"></script> <script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/ncids-common.js?smm34w"></script> <script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/blogs.js?smm34w"></script> </body> </html>

CINXE.COM

FDA Approvals - Cancer Currents Blog - NCI